TRPM8 and prostate carcinoma: The research investigates how the encapsulated WS12 affects the migration of prostate cancer cells mediated by TRPM8 both in vivo and in vitro, and demonstrates WS12’s affinity and specificity for TRPM8 by making it a successful channel agonist.